In general terms DEAP-HUS affects young patients (ca 4–17 years of age) and most autoantibodies bind to the C-terminal recognition region of Factor H (SCRs19-20) and block Factor H surface binding. The gene discussed is CFH; the disease is hemolytic-uremic syndrome.